Clinic
Chca Clear Lake LP
Chca Clear Lake LP was paid $17.46M by Medicaid between Jan 2020 and Dec 2024, across 87 billing codes. Its largest line is 99284, emergency room visit (serious) — 45% of everything it billed.
33Billing provider infoCHCA CLEAR LAKE LP
WEBSTER, TX 77598
WEBSTER, TX 77598
33aNPI1063466035assigned 05/22/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$17.46M
24GClaims161,575
24DCodes billed87
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#27 of 320
Median peer was paid$205K
This provider vs. median85×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JONES, STEPHEN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,982 | $882K | |
| 2021 | 38,098 | $5.03M | |
| 2022 | 50,675 | $5.13M | |
| 2023 | 47,266 | $4.68M | |
| 2024incomplete | 21,554 | $1.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 45% | 15,650 | 14,765 | $7.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 36,840 | 35,617 | $5.63M |
| 41899 | Unlisted procedure, dentoalveolar structures | 7.8% | 233 | 230 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 3,093 | 3,025 | $474K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.4% | 55 | 54 | $240K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 3,157 | 2,841 | $196K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,117 | 3,034 | $166K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,114 | 4,961 | $126K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,071 | 6,737 | $119K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 95 | 88 | $110K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 42 | 42 | $108K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,114 | 4,001 | $102K |
75 more codes
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 541 | $91K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,487 | $85K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,114 | $81K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,094 | $79K |
| 99285 | Emergency room visit (most serious) | <1% | 977 | $63K |
| 85027 | <1% | 15,428 | $60K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,707 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 342 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 992 | $42K |
| 81001 | <1% | 12,618 | $39K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,907 | $37K |
| 80053 | Comprehensive metabolic panel | <1% | 2,650 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 825 | $24K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 245 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 128 | $19K |
| 84703 | <1% | 2,627 | $19K | |
| 93976 | <1% | 182 | $15K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 45 | $15K |
| 80047 | <1% | 423 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,082 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 68 | $13K |
| 87430 | <1% | 1,233 | $13K | |
| 80076 | <1% | 2,046 | $13K | |
| 76801 | <1% | 138 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 218 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,195 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 251 | $8K |
| 84484 | <1% | 1,915 | $8K | |
| 87634 | <1% | 188 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 215 | $7K |
| 87420 | <1% | 740 | $7K | |
| 88304 | <1% | 85 | $6K | |
| 83690 | <1% | 1,585 | $5K | |
| 84702 | <1% | 461 | $4K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 79 | $3K |
| 83880 | <1% | 439 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 59 | $2K |
| 87081 | <1% | 420 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 248 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 26 | $2K |
| 82248 | <1% | 969 | $1K | |
| 74018 | <1% | 65 | $1K | |
| 86850 | <1% | 125 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15 | $1K |
| 85610 | <1% | 1,040 | $863.61 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,179 | $851.09 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 336 | $777.32 |
| 76818 | <1% | 12 | $604.15 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 579 | $589.53 |
| 86901 | <1% | 656 | $585.13 | |
| 86900 | <1% | 656 | $585.03 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $515.47 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 564 | $502.49 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 18 | $483.93 |
| 85730 | <1% | 483 | $474.55 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 24 | $449.46 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 24 | $382.68 |
| 82731 | <1% | 18 | $381.40 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 72 | $349.34 |
| 83735 | <1% | 144 | $232.08 | |
| 80321 | <1% | 14 | $116.39 | |
| 87040 | <1% | 43 | $80.26 | |
| 83605 | <1% | 54 | $58.32 | |
| 86140 | <1% | 13 | $34.89 | |
| 81003 | <1% | 43 | $19.09 | |
| 87186 | <1% | 16 | $14.54 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 51 | $13.78 |
| J2704 | Injection, propofol, 10 mg | <1% | 28 | $6.50 |
| A9270 | Non-covered item or service | 0% | 2,282 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 34 | $0.00 |
| 72170 | 0% | 14 | $0.00 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 339 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 19 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJONES, STEPHEN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Cherokee Nation | Tahlequah, OK | $6.38M |
| Norfolk City Public Schools | Norfolk, VA | $5.77M |
| Louisiana Academic Health Network, LLC | New Orleans, LA | $2.79M |
| Blue Ridge Hospice INC. | Winchester, VA | $1.58M |
| Cherokee Nation | Muskogee, OK | $609K |
| Carver Community Clinic, LLC | New Orleans, LA | $475K |
| Cherokee Nation | Vinita, OK | $434K |
| Cherokee Nation | Ochelata, OK | $330K |
| Cherokee Nation | Stilwell, OK | $177K |
| Cherokee Nation | Salina, OK | $119K |
| Cherokee Nation | Jay, OK | $103K |
| Cherokee Nation | Nowata, OK | $35K |
| Cherokee Nation | Sallisaw, OK | $35K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.